In humans the skeletal musculature can constitute over 50% of the body mass, and a range of anatomical, physiological and cellular features makes this tissue an attractive candidate for gene transfer procedures designed to augment normal gene function, express heterologous therapeutic products or immunize the host organism. Under normal conditions, skeletal myofibres are stable post-mitotic cells with good vascularity and, if necessary, high regenerative capacity. Tissues are easily accessible for administration of genetic vehicles and, if necessary, for removal of treated areas. In addition, myofibres are multinucleated cells deriving from the fusion of mononucleate stem (or precursor) cells known as satellite cells. The syncytial nature of the myofibres means that limited gene delivery to a few nuclei may lead to expression of the cognate gene product over a considerable area, and that engineering of satellite cells in tissue culture allows an efficient mechanism of ex vivo gene transfer via transplantation and fusion into existing myofibre cells. T h e transfer of genetic material to skeletal muscle has been proposed for inherited neuromuscular diseases such as Duchenne muscular dystrophy (DMD), for disorders affecting mucopolysaccharide, carbohydrate, amino acid or lipid metabolism, for common acquired disorders such as diabetes mellitus, hyperlipidaemia and cardiovascular disease, and for vaccination against a number of infectious agents. An extensive range of gene transfer techniques have now been applied to muscle tissues. On the one hand there are virus-based vector systems. Viruses have evolved highly efficient mechanisms for evading the host immune defence and delivering their genetic material to the nucleus, and an immense amount of research has been directed at harnessing these properties to deliver foreign genes using genetically modified viruses. As the major objective of gene therapy is long-term expression, deletion of key regulatory viral genes is essential to ensure replication deficiency and that infection does not lead to target cell death.
Abbreviation used: DMD, Duchenne muscular dystrophy.
In terms of gene transfer to muscle, adenoviral and retroviral vectors have been most thoroughly examined. In addition, significant efforts have been invested in developing DNA-mediated gene transfer procedures using liposome, polyamine and other carrier systems.
In terms of gene therapy, the simplest, most inexpensive and possibly the safest procedure is the direct administration of pure DNA to a desired tissue. Wolff [6-81. T h e fact that regenerating muscle has a higher efficiency of transfection may be advantageous for gene therapy in disorders, such as DMD, in which regenerating fibres are numerous in the early stages. Striated muscle seems to be particularly efficient at plasmid DNA uptake compared with other tissues [3] . However, the mechanism by which the naked DNA enters myofibres remains undefined, but it does not appear to be the result of overt injury to the sarcolemmal membrane [5] . Wells and Goldspink [9] demonstrated that the uptake efficiency in mice is dependent on the age and sex. Moreover, Davis and co-workers [5] showed that pure plasmid DNA is unable to transfect mononucleated muscle cell precursors in toxin-treated muscle and that transfection only becomes efficient at certain levels of fibre maturity. They postulated that this may be associated with the Volume 
24
presence of t-tubules. Further evidence was supplied by electron microscopic studies showing that injected plasmid DNA conjugated to colloidal gold is associated with t-tubules [9] .
In terms of direct physical gene transfer, a number of mechanisms to enhance DNA uptake have been proposed. These include DNA-coated particle bombardment [ [14] [15] [16] . This technique relies upon the electrical charge properties of polycationic lipids, which spontaneously bind polyanionic DNA or FWA. Zhu and co-workers [ 151 have recently reported that a single systemic injection of an expression plasmidcationic liposome complex into adult mice efficiently transfected many different tissues. In a recent report, Trivedi and Dickson [ 161 showed efficient transfer of dystrophin cDNA into primary muscle cultures using liposome vehicles.
Adenoviruses are attractive vectors for gene therapy as they are highly stable, exhibit wide tropism and can infect quiescent as well as dividing cells. Respiratory epithelium is the primary target of normal infection, but other major sites include the eye and the gastrointestinal and urinary tracts [17] . Most adenoviral infections are subclinical, resulting only in antibody formation, and the safety of clinical adenovirus administration has been verified over the past 20 years with more than ten million human subjects having received oral vaccines of live virus with no detectable toxicity [ 181. Additional advantageous properties of adenovirus vectors are that the viral particles can be purified and concentrated to high titre (approx. 10" plaque-forming units/ml), making systemic clinical administration feasible, and that the genome is relatively easy to manipulate and does not normally undergo rearrangement at a high rate. The adenovirus genome rarely integrates into the host chromosome and replicates in an extrachromosomal state. This greatly reduces the risk of insertional mutagenesis but renders transduction relatively transient in many cells. However, as noted above, the postmitotic nature and stability of muscle fibres appear to permit the long-term expression of transferred genes even in the extrachromosomal form.
One current limitation of adenovirus vectors is a relatively tight upper size limit for DNA packaging of approximately 105% of the wildtype genome. Above this, sharp reductions in viral yields and stability are observed owing to rapid rearrangements [ 191. Even with El/E3-deleted adenoviral vectors the capacity for foreign DNA insertion is restricted to about 7.8 kb [20] and hence, for example, cannot accommodate full-length dystrophin cDNAs. Nevertheless, in this case a 6.3 kb human minidystrophin cDNA isolated from one patient with very mild clinical manifestations of Becker MD has been used to construct EUE3-deleted recombinant adenovirus vectors ( [21, 22] , G. Dickson, unpublished work). In vivo studies involving intramuscular injections into neonatal mdx mice have shown that these adenovirus vectors can efficiently direct the synthesis of a significant amount of the 229 kDa minidystrophin, with 5-50% of fibres showing correct sarcolemmal localization. In one study dystrophin-transduced muscle showed only approx. 12% regeneration compared with over 60% in age-matched control mdx muscle. Under these conditions dystrophin expression was reported up to 6 months after virus injection with no histopathological alterations or cytotoxic immune responses [23] .
T h e route of adenovirus administration is a major factor in terms of transduction efficiencies to different tissues. After systemic administration of a recombinant adenovirus vector, expression of transgenes in a variety of different organs and tissues is generally found. Kass-Eisler and coworkers [24] have reported that administration of recombinant adenovirus into rats via six different routes resulted in the infection of all eight tissues tested, but to varying degrees. The most effective and widespread method of gene transfer was found surprisingly to be via intracardiac injection. In terms of gene transfer to skeletal muscle, intramuscular injection resulted in equivalent efficiencies as via the intracardial route. It has also been shown that the infectivity of muscle and other organs by adenovirus vectors is very much dependent on the maturity of the tissue and/or age of the treated animal. Immature muscle cells are efficiently transduced but mature muscle fibres are not, even at high titres ( [25, 26] ([30,31] , G. Dickson, unpublished work), have been deleted, leaving only minimal sequence elements necessary for replication and packaging. Such vectors have been proposed to provide potentially up to 35 kb of insert capacity, which would allow the use of complex promoter elements and linked reporter genes, and for example the fulllength dystrophin cDNA. In addition, minimal vector systems would eliminate secondary cellmediated immune responses to infected cells. At present, such systems require so-called helper virus for capsid assembly and packaging, but complementation strategies using packagingdefective viral genomes are being tested.
Recombinant retroviruses based on mouse C-type retroviruses are another viral vector system widely used for gene transfer in animals and humans. Several features render recombinant retroviruses suitable for gene transfer in skeletal muscle. The retroviral genome is stably integrated into host cell DNA, and thus retroviruses have the potential for indefinite expression of the recombinant protein. Once integrated, viral promoter and enhancer elements can be used to drive transcription of the inserted genes in many cell types, including myoblasts and myotubes. Moreover, skeletal muscle transfected by retroviral vectors may theoretically show both biochemical and genetic normalization. These vectors are genetically engineered so that all proteins necessary for viral replication can be provided in trans, generating infectious particles that do not produce viral antigens once infection has occurred. The main limitations of retroviral vectors are the limited insert size that they can accommodate (9-10 kb) and the fact that only cells that are in, or close to, mitosis can be transduced [32] . As the retroviral genome is able to integrate into host cell chromatin, both ex vivo and in vivo approaches are feasible for gene transfer in skeletal muscle. In the ex vivo approach target cells from the patient are infected in vitro by recombinant retroviruses followed by autologous transplantation [33-351. Retroviral vectors have been used to infect muscle cells in vitro, and expression of the transgene has been detected after myoblast fusion into myotubes, indicating that profound changes in cell transcription pattern do not necessarily affect retroviral gene expression [36] . After this initial in vitro study performed with a reporter gene, a recombinant retrovirus carrying the 229 kDa dystrophin cDNA has been constructed and used to infect mdx myoblasts, resulting in the expression and correct localization of the protein at the sarcolemma of the skeletal muscle myotubes [37] . As recombinant retrovirus expression in most cases is not developmentally regulated, the study also confirmed that dystrophin expression in myoblasts does not interfere with the normal process of fusion and myotube formation. Indeed, studies in various mouse models showed that myoblasts transduced in vitro with retroviral vectors are able to fuse with pre-existing myofibres when transplanted in vivo and are able to However, the expression of the recombinant gene after implantation in vivo is somehow transient in primary myoblasts, and sustained expression has been obtained only using heterologous enhancer-promoter sequences [33] .
Direct in vivo administration of recombinant virus has also been attempted [37] . Although myofibres are post-mitotic syncytia and refractory to infection with retroviruses, during the process of muscle regeneration activated satellite cells can be targeted by recombinant retroviruses. Experimental degeneration of muscle can be artificially induced in normal mice; alternatively, mdx mice can be used, in which spontaneous muscle degeneration-regeneration is ongoing [37] . However, direct injection of retrovirus-containing supernatants into regenerating mouse skeletal muscle results in relatively low efficiency of transduction, possibly because of the limited temporal availability of dividing satellite cells at the precise time of infection and because of interference by the immune system, which reduces the already short half-life of retroviruses in vivo [40] . Some of these problems have been overcome by direct injection of mitotically inactivated retroviral producer cells into regenerating skeletal muscle, resulting in a much higher efficiency of transduction and in the infection of satellite cells that contributed to new fibre formation in the longterm (G. Dickson, unpublished work Although there are many hurdles that have as yet to be overcome on the route to developing acceptable gene therapy protocols targeted to the skeletal musculature, it is encouraging to note the speed at which progress is being made. It is unlikely that a single delivery system will provide the perfect panacea for gene therapy, although advances in viral vector development provide hope for future treatment protocols. A better understanding of basic muscle cell biology is also clearly necessary for the development and improvement of therapeutic reagents and treatment strategies, and issues of stability of expression, immune responses and viral mobilization need to be carefully examined. Finally, it must be emphasized that much of the in vivo work published to date has pertained to mouse model systems, and it will be essential to reproduce and extend these studies in large animal models before plans for human clinical trials can be sensibly put forward and considered.
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